{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T22:28:52Z","timestamp":1759616932143,"version":"3.44.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.encep.2021.04.009","type":"journal-article","created":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T06:00:03Z","timestamp":1627106403000},"page":"404-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antid\u00e9presseurs et hypertension art\u00e9rielle\u00a0: \u00e9tude cas \/non-cas dans la base nationale de pharmacovigilance"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4369-7237","authenticated-orcid":false,"given":"A.","family":"Hofferer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Dolladille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7483-2489","authenticated-orcid":false,"given":"B.","family":"Chretien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sassier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Laugier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Atzenhoffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fedrizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2747-9229","authenticated-orcid":false,"given":"X.","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.encep.2021.04.009_bib0210","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1161\/01.CIR.92.9.2437","article-title":"Blood pressure and mortality among men with prior myocardial infarction. Multiple risk factor intervention trial research group","volume":"92","author":"Flack","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.encep.2021.04.009_bib0215","doi-asserted-by":"crossref","first-page":"I13","DOI":"10.1161\/01.HYP.13.5_Suppl.I13","article-title":"Blood pressure as a risk factor for cardiovascular disease. The Framingham Study\u201330\u00a0years of follow-up","volume":"13","author":"Stokes","year":"1989","journal-title":"Hypertension"},{"key":"10.1016\/j.encep.2021.04.009_bib0220","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejphar.2015.06.027","article-title":"Drug induced hypertension\u2013An unappreciated cause of secondary hypertension","volume":"763","author":"Grossman","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.encep.2021.04.009_bib0225","first-page":"39","article-title":"Pharmaco-epidemiologic study of the use of antidepressant drugs in the general population","volume":"22","author":"Rouillon","year":"1996","journal-title":"Encephale"},{"key":"10.1016\/j.encep.2021.04.009_bib0230","first-page":"411","article-title":"Antidepressants consumption in the global population in France","volume":"28","author":"Oli\u00e9","year":"2002","journal-title":"Encephale"},{"key":"10.1016\/j.encep.2021.04.009_bib0235","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3109\/09638237.2014.924047","article-title":"Depression is linked to uncontrolled hypertension: a case-control study from Karachi, Pakistan","volume":"23","author":"Almas","year":"2014","journal-title":"J Ment Health"},{"key":"10.1016\/j.encep.2021.04.009_bib0240","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.jocn.2015.03.067","article-title":"Antidepressant medication can improve hypertension in elderly patients with depression","volume":"22","author":"Fu","year":"2015","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.encep.2021.04.009_bib0245","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1097\/HJH.0b013e32834c465d","article-title":"Drug-related hypertension and resistance to antihypertensive treatment: a call for action","volume":"29","author":"Rossi","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.encep.2021.04.009_bib0250","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1161\/HYPERTENSIONAHA.108.126698","article-title":"Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension","volume":"53","author":"Licht","year":"2009","journal-title":"Hypertension"},{"issue":"Suppl 1","key":"10.1016\/j.encep.2021.04.009_bib0255","first-page":"13S","article-title":"Effect of mianserin hydrochloride on peripheral uptake mechanisms for noradrenaline and 5-hydroxytryptamine in man","volume":"5","author":"Coppen","year":"1978","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.encep.2021.04.009_bib0260","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s001150050166","article-title":"Mianserin-induced hypertension 2\u00a0weeks after discontinuation of tranylcypromine","volume":"68","author":"Bottlender","year":"1997","journal-title":"Nervenarzt"},{"key":"10.1016\/j.encep.2021.04.009_bib0265","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1365-2125.1997.00615.x","article-title":"Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case\/non-case study in the French pharmacovigilance system database","volume":"44","author":"Moore","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.encep.2021.04.009_bib0270","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002018-200225060-00010","article-title":"Use of measures of disproportionality in pharmacovigilance: three Dutch examples","volume":"25","author":"Egberts","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.encep.2021.04.009_bib0275","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.encep.2021.04.009_bib0280","first-page":"111","article-title":"Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France","volume":"40","author":"B\u00e9gaud","year":"1985","journal-title":"Therapie"},{"key":"10.1016\/j.encep.2021.04.009_bib0285","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.encep.2021.04.009_bib0290","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.encep.2021.04.009_bib0295","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S0140-6736(64)91553-3","article-title":"Hypertensive crisis associated with monoamine-oxidase inhibitors","volume":"1","author":"Blackwell","year":"1964","journal-title":"Lancet"},{"key":"10.1016\/j.encep.2021.04.009_bib0300","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00004714-198902000-00011","article-title":"Autoinduction of hypertensive reactions by tranylcypromine?","volume":"9","author":"Keck","year":"1989","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.encep.2021.04.009_bib0305","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2012.03.026","article-title":"Cardiovascular baroreceptor activity and selective inhibition of monoamine oxidase","volume":"683","author":"Bar-Am","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.encep.2021.04.009_bib0310","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/S0140-6736(95)91711-X","article-title":"Hypertension with moclobemide","volume":"346","author":"Coulter","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.encep.2021.04.009_bib0315","first-page":"38","article-title":"Mysterious MAOI hypertensive episodes","volume":"49","author":"Kahn","year":"1988","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2021.04.009_bib0320","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0006-3223(93)90384-P","article-title":"Spontaneous hypertensive reactions with monoamine oxidase inhibitors","volume":"34","author":"Lavin","year":"1993","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.encep.2021.04.009_bib0325","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-2007-979193","article-title":"Undesirable blood pressure changes under naturalistic treatment with moclobemide, a reversible MAO-A inhibitor\u2013results of the drug utilization observation studies","volume":"32","author":"Delini-Stula","year":"1999","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.encep.2021.04.009_bib0330","doi-asserted-by":"crossref","first-page":"502","DOI":"10.4088\/JCP.v59n1002","article-title":"Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744\u00a0depressed patients","volume":"59","author":"Thase","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2021.04.009_bib0335","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1097\/01.JGP.0000204328.50105.b3","article-title":"Cardiovascular changes associated with venlafaxine in the treatment of late-life depression","volume":"14","author":"Johnson","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.encep.2021.04.009_bib0340","first-page":"67","article-title":"Duloxetine-induced hypertension: a case report","volume":"27","author":"Mermi","year":"2016","journal-title":"Turk Psikiyatri Derg"},{"key":"10.1016\/j.encep.2021.04.009_bib0345","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0163-8343(01)00143-8","article-title":"Even low-dose treatment of venlafaxine may provoke recurrence of hypertension in an Asian patient?","volume":"23","author":"Bahk","year":"2001","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.encep.2021.04.009_bib0350","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-2006-958723","article-title":"Hypertension induced by regular doses of milnacipran: a case report","volume":"40","author":"de\u00a0Toledo\u00a0Ferraz\u00a0Alves","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.encep.2021.04.009_bib0355","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/00004714-199710000-00019","article-title":"Clomipramine-induced pheochromocytoma crisis: a near fatal complication of a tricyclic antidepressant","volume":"17","author":"Korzets","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.encep.2021.04.009_bib0360","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/fcp.12440","article-title":"Hypertension induced by serotonin reuptake inhibitors: analysis of two pharmacovigilance databases","volume":"33","author":"Humbert","year":"2019","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.encep.2021.04.009_bib0365","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000447034","article-title":"The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature","volume":"85","author":"Carvalho","year":"2016","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.encep.2021.04.009_bib0370","first-page":"9","article-title":"Tianeptin (coaxil) in therapy of depression in cardiovascular patients","volume":"80","author":"Tsygankov","year":"2008","journal-title":"Ter Arkh"},{"key":"10.1016\/j.encep.2021.04.009_bib0375","doi-asserted-by":"crossref","unstructured":"Watts S, Morrison S, Davis R, Barman S. Serotonin and blood pressure regulation. Pharmacol Rev n.d.;64:359-88.","DOI":"10.1124\/pr.111.004697"},{"key":"10.1016\/j.encep.2021.04.009_bib0380","first-page":"653","article-title":"Paroxetine is a novel nitric oxide synthase inhibitor","volume":"32","author":"Finkel","year":"1996","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.encep.2021.04.009_bib0385","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjmed.2011.05.024","article-title":"Drug-induced hypertension: an unappreciated cause of secondary hypertension","volume":"125","author":"Grossman","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.encep.2021.04.009_bib0390","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/026988110001400101","article-title":"Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993\u00a0British Association for Psychopharmacology guidelines. British Association for Psychopharmacology","volume":"14","author":"Anderson","year":"2000","journal-title":"J Psychopharmacol (Oxford)"},{"key":"10.1016\/j.encep.2021.04.009_bib0395","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ancard.2015.04.007","article-title":"Hypertension in the elderly in France: Characteristics of treatments and frequency of cognitive complaint according to the 2014\u00a0French league against hypertension survey","volume":"64","author":"Girerd","year":"2015","journal-title":"Ann Cardiol Angeiol (Paris)"},{"key":"10.1016\/j.encep.2021.04.009_bib0400","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1001\/jama.288.13.1588","article-title":"Rates of spontaneous reporting of adverse drug reactions in France","volume":"288","author":"B\u00e9gaud","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.encep.2021.04.009_bib0405","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.encep.2021.04.009_bib0410","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case-non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001370062100155X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001370062100155X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T17:41:50Z","timestamp":1757958110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001370062100155X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S001370062100155X"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2021.04.009","relation":{},"ISSN":["0013-7006"],"issn-type":[{"type":"print","value":"0013-7006"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antid\u00e9presseurs et hypertension art\u00e9rielle\u00a0: \u00e9tude cas \/non-cas dans la base nationale de pharmacovigilance","name":"articletitle","label":"Article Title"},{"value":"L'Enc\u00e9phale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.encep.2021.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 L'Enc\u00e9phale, Paris.","name":"copyright","label":"Copyright"}]}}